2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Vimpat ® – Improved seizure control Regardless of patient’s concomitant therapy 14
UCB’s status as the company with the best reputation amongst neurologists continues to grow 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% July 2006, Previous ATU (n=101) UCB GlaxoSmithKline Abbott Laboratories Pfizer Ortho McNeil Novartis Don't know None Q58a. When thinking of pharmaceutical companies that manufacture anti-epileptic products, which one company would you say has the best reputation in epilepsy/seizure disorder category? (open-end) Company with Best Reputation (Unaided) All Neurologists Feb 2007, Previous ATU (n=106) Nov 2007, Previous ATU (n=100) August 2008 (n=150) June 2009 (n=151) January 2010 (n=201) June 2010 (n=178) Source: ATU July 2010 15
Page 1 and 2: 2010 full-year results 3 March 2011
Page 3 and 4: UCB: to be patient-centric global b
Page 5 and 6: 203 000 patients have now been trea
Page 7 and 8: U.S. Business Greg Duncan, Presiden
Page 9 and 10: Cimzia ® provides a fast response
Page 11 and 12: Cimzia ® in rheumatoid arthritis -
Page 13: Vimpat ® U.S. When monotherapy is
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21 and 22: Cimzia ® roll-out in Europe and Re
Page 23 and 24: Vimpat ® in epilepsy Roll-out in E
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39 and 40: Advancing the pipeline Iris Loew-Fr
Page 41 and 42: Development pipeline with significa
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54: Significant Pipeline Q2 January pip
Page 55 and 56: UCB's Sustainable Growth Roch Doliv
Page 57 and 58: UCB's sustainable future growth Cim
Page 59 and 60: Appendix 59 59
Page 61 and 62: Geographic and therapeutic breakdow
Page 63 and 64: 2010 balance sheet € million Cash
Page 65 and 66:
Shareholder structure 1 Strong and
Page 67 and 68:
Cimzia ® in further arthritis indi
Page 69 and 70:
CDP7851 in bone loss disorders Nove
Page 71 and 72:
Vimpat ® in epilepsy Increasing pa
Page 73:
Your UCB Investor Relations team An
show all

2010 full-year results 3 March 2011 - UCB

Create successful ePaper yourself

Delete template?

Save as template?